| 1 |
Mayr FB, Yende S, Linde-Zwirble WT, et al. Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis[J]. JAMA, 2010, 303(24): 2495-2503.
|
| 2 |
Vincent JL, Rello J, Marshall J, et al. EPIC Ⅱ Group of investigators international study of the prevalence and outcomes of infection in intensive care units[J]. JAMA, 2009, 302(21): 2323-2329.
|
| 3 |
Elfeky S, Golabi P, Otgonsuren M, et al. The epidemiologic characteristics，temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study[J]. J Crit Care, 2017, 39: 48-55.
|
| 4 |
Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts[J]. JAMA, 2014, 312(1): 90-92.
|
| 5 |
Jones AE, Puskarich MA. The surviving sepsis campaign guidelines 2012: update for emergency physicians[J]. Ann Emerg Med, 2014, 63(1): 35-47.
|
| 6 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 45(3): 486-552.
|
| 7 |
Ventura AM, Shieh HH, Bousso A, et al. Double-blind prospective randomized controlled trial of dopamine versus epinephrine as first-Line vasoactive drugs in pediatric septic shock[J]. Crit Care Med, 2015, 43(11): 2292-2302.
|
| 8 |
Annane D, Renault A, Bellissant E. Glucocorticoids with or without fludrocortisone in septic shock[J]. N Engl J Med, 2018, 379(9): 895-896.
|
| 9 |
Cardenas-Garcia J, Schaub KF, Belchikov YG, et al. Safety of peripheral intravenous administration of vasoactive medication[J]. J Hosp Med, 2015, 10(9): 581-585.
|
| 10 |
Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe investigators[J]. Intensive Care Med, 2015, 41(9): 1549-1560.
|
| 11 |
Osborn TM. Severe sepsis and septic shock trials (ProCESS, ARISE，ProMISe): What is optimal resuscitation？[J]. Crit Care Clin, 2017, 33(2): 323-344.
|
| 12 |
Antunes M, Scirè CA, Talarico R, et al. Undifferentiated connective tissue disease: state of the art on clinical practice guidelines[J]. RMD Open, 2018, 4(Suppl 1): e000786.
|
| 13 |
Kelly BT, Moua T. Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality[J]. Respirology, 2018, 23(6): 600-605.
|
| 14 |
Luciano N, Baldini C, Tarantini G, et al. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren′s syndrome from undifferentiated connective tissue diseases[J]. Rheumatology (Oxford), 2015, 54(12): 2198-2204.
|
| 15 |
Koo SM, Uh ST. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist′s point of view[J]. Korean J Intern Med, 2017, 32(4): 600-610.
|
| 16 |
Gao Y, Moua T. Treatment of the connective tissue disease-related interstitial lung diseases: a narrative review[J]. Mayo Clin Proc, 2020, 95(3): 554-573.
|
| 17 |
Pepmueller PH. Undifferentiated connective tissue disease, mixed connective tissue disease, and overlap syndromes in rheumatology[J]. Mo Med, 2016, 113(2): 136-140.
|
| 18 |
Yang S, Ni R, Lu Y, et al. A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for living fetuses (ILIFE) trial[J]. Trials, 2020, 21(1): 771.
|
| 19 |
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease[J]. BMJ, 2016, 352: h6819.
|
| 20 |
García-González M, Rodríguez-Lozano B, Bustabad S, et al. Undifferentiated connective tissue disease: predictors of evolution into definite disease[J]. Clin Exp Rheumatol, 2017, 35(5): 739-745.
|
| 21 |
Riccardi A, Marcoccia A, Borgia A, et al. Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify patients who will evolve[J]. Autoimmun Rev, 2019, 18(9): 102358.
|
| 22 |
Chernau AK, Leone PM, Swigris JJ. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease[J]. Semin Respir Crit Care Med, 2019, 40(2): 271-277.
|